(R)-N-(2-(ethylsulfonyl)ethyl)-2-(4-fluoro-3-(trifluoromethyl)phenyl)-N-(1-(1-(4-iodophenyl)-1H-benzo[d]imidazol-2-yl)ethyl)acetamide | 1010857-91-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: (R)-N-(2-(ethylsulfonyl)ethyl)-2-(4-fluoro-3-(trifluoromethyl)phenyl)-N-(1-(1-(4-iodophenyl)-1H-benzo[d]imidazol-2-yl)ethyl)acetamide
• CAS: 1010857-91-6
• 化学式: C₂₈H₂₆F₄IN₃O₃S
• 分子量: 687.497
• InChiKey: ZEDBMLNANVQFKN-GOSISDBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.36
• 重原子数：
  40.0
• 可旋转键数：
  9.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  72.27
• 氢给体数：
  0.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  (R)-N-(2-(ethylsulfonyl)ethyl)-2-(4-fluoro-3-(trifluoromethyl)phenyl)-N-(1-(1-(4-iodophenyl)-1H-benzo[d]imidazol-2-yl)ethyl)acetamide 、 氰化钠 在 四(三苯基膦)钯 copper(l) iodide 作用下， 以 乙腈 为溶剂， 以92%的产率得到(R)-N-(1-(1-(4-cyanophenyl)-1H-benzo[d]imidazol-2-yl)ethyl)-N-(2-(ethylsulfonyl)ethyl)-2-(4-fluoro-3-(trifluoromethyl)phenyl)acetamide
  参考文献：
  名称：

  Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists

  摘要：

  A series of six-six and six-five fused heterocyclic CXCR3 antagonists has been synthesized and their activities evaluated in an [I-125]-IP-10 displacement assay and an ITAC mediated in vitro cell migration assay. The pharmacokinetic properties of several top compounds have also been studied. This effort led to the discovery of compounds with increased potency and improved pharmacokinetic properties that could serve as useful tools to study the role of the CXCR3 receptor in vivo. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.11.060
• 作为产物：
  描述：

  4-氟-3-(三氟甲基)苯乙酸 、 在 N-甲基吗啉 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (R)-N-(2-(ethylsulfonyl)ethyl)-2-(4-fluoro-3-(trifluoromethyl)phenyl)-N-(1-(1-(4-iodophenyl)-1H-benzo[d]imidazol-2-yl)ethyl)acetamide
  参考文献：
  名称：

  Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists

  摘要：

  A series of six-six and six-five fused heterocyclic CXCR3 antagonists has been synthesized and their activities evaluated in an [I-125]-IP-10 displacement assay and an ITAC mediated in vitro cell migration assay. The pharmacokinetic properties of several top compounds have also been studied. This effort led to the discovery of compounds with increased potency and improved pharmacokinetic properties that could serve as useful tools to study the role of the CXCR3 receptor in vivo. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.11.060